Zacks Research Has Optimistic Outlook of COO Q3 Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Analysts at Zacks Research boosted their Q3 2025 EPS estimates for Cooper Companies in a research note issued to investors on Tuesday, December 24th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical device company will earn $1.05 per share for the quarter, up from their previous forecast of $1.04. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ FY2025 earnings at $3.98 EPS, Q1 2026 earnings at $1.02 EPS, Q2 2026 earnings at $1.06 EPS, Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.42 EPS and FY2027 earnings at $4.86 EPS.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.87 EPS.

Several other brokerages also recently issued reports on COO. Citigroup lowered their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Morgan Stanley lowered their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lifted their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Stock Performance

Shares of NASDAQ:COO opened at $92.34 on Friday. The business’s 50-day simple moving average is $100.66 and its 200 day simple moving average is $98.86. The company has a market cap of $18.43 billion, a P/E ratio of 47.35, a PEG ratio of 2.52 and a beta of 0.97. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. Cooper Companies has a one year low of $84.76 and a one year high of $112.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ashton Thomas Securities LLC bought a new position in Cooper Companies during the third quarter valued at about $25,000. Innealta Capital LLC bought a new position in shares of Cooper Companies during the 2nd quarter valued at about $25,000. Covestor Ltd grew its stake in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after purchasing an additional 200 shares during the last quarter. Crewe Advisors LLC raised its holdings in shares of Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares in the last quarter. Finally, Tortoise Investment Management LLC lifted its stake in Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.